Skip to main content

Rett Syndrome clinical trials at UC Davis

1 research study open to eligible people

Showing trials for
  • A Study of the Experimental Medicine ANAVEX2-73 For Rett Syndrome

    open to eligible females ages 18-45

    Phase 2 safety, tolerability and efficacy study is designed as a double-blind, randomized, placebo-controlled study. 7-week placebo-controlled study of ANAVEX2-73 oral solution for the treatment of patients with RTT 18 years or older. A voluntary option will be offered for all patients who meet the exposure criteria for ANAVEX2-73 to continue a 12-week open label extension.

    Sacramento, California and other locations

Last updated: